Top Industry Leaders in the IBS Treatment Market
Latest Irritable Bowel Syndrome (IBS) Treatment Companies Updates:
Ironwood Pharmaceuticals: Promising Phase 3 data for Linzess (linaclotide) in adult IBS-C patients with constipation-predominant symptoms, potentially expanding treatment options.
Takeda Pharmaceuticals: Positive Phase 2a results for TAK-786, a novel oral guanylate cyclase-C (GC-C) stimulator, showing potential for treating both IBS-C and IBS-D.
Allergan: Launched a Phase 2 study for AG041270, a new investigational therapy targeting neurokinin-1 (NK-1) receptors, for treating IBS-D.
AstraZeneca: Received FDA approval for Trinessa (drospirenone, ethinyl estradiol, and levofloxacin) for treating moderate-to-severe IBS-C in women with endometriosis.
Suven Therapeutics: Launched SB207798, a first-in-class, peripherally acting G-protein coupled receptor 54 (GPR54) agonist, for treating CIC in adults, which could potentially be repurposed for IBS in the future.
Synergy Pharmaceuticals: Expanded market access for Trulance (plecanatide) in Canada for treating adults with IBS-C.
List of Irritable Bowel Syndrome (IBS) Treatment Key companies in the market:
- Allergan Plc (Ireland)
- Sucampo Pharmaceuticals (U.S.)
- Ironwood Pharmaceuticals, Inc. (U.S.)
- Astellas Pharma Inc. (Japan)
- Valeant Pharmaceuticals (Canada)
- Abbott Laboratories (U.S.)
- Synergy Pharmaceuticals, Inc. (U.S.)
- Ardelyx, Inc. (U.S.)
- Nestle (Switzerland)
- Sebela Pharmaceuticals (Ireland)
- Probi (Sweden)
- Alfasigma USA, Inc. (Italy)